Sigma Healthcare's Boots Flirtation Gives Way to a Real Growth Crack

A near-$15 billion UK gamble came and went, and a first genuine sales deceleration is now testing whether Chemist Warehouse's owner deserves its rich multiple.

30 Sep 2026 · 3 min read

Sigma Healthcare has been at the centre of a sharp valuation debate, with the Chemist Warehouse owner's roughly 50 times earnings multiple splitting fund managers between those who see genuine category-killer strength and those who think the price already assumes near-perfect execution, a tension that intensified when Sigma flirted with a roughly A$15 billion bid for UK chain Boots before walking away.

Accelerating sales, a UK entry, and a valuation debate

Ten Cap's Jun Bei Liu named Sigma her top pick, arguing that while the consumer is under pressure, selective names with strong brand and pricing power can still perform. Pendal Group said sales momentum accelerated from 12.2 percent in January and February to 14.4 percent in March and April, with Sigma also announcing entry to the UK market through a joint venture with Greenlight Healthcare, a loss-making, financially distressed network of 22 stores around London, in which Sigma holds 75 percent. Paradice Investment Management held at hold, liking the Chemist Warehouse powerhouse with mid-teens like-for-like comparable sales growth, probably the best retailer in Australia, but cautioning that expectations are very high given the multiple it trades on, meaning growth really needs to accelerate from here. Alliance Bernstein rated it a sell, questioning a 50 times earnings multiple for a business that, in its words, sells perfumes and pills rather than AI, and noting the company's structure came from a reverse merger rather than a traditional IPO. Quest Asset Partners added the stock, viewing it as an attractive consumer-facing business with strong quality characteristics and relatively lower exposure to emerging AI-driven shopping disruption, with recent RBA actions creating the entry opportunity.

It's 50 times PE. It's not an AI stock. They sell perfumes and pills, right? If they achieve the growth implied by that share price, we're all going to smell great and be really healthy.

— Alliance Bernstein, Article, May 2026

A near A$15 billion Boots gamble, then a retreat

Pendal Group said the stock fell 9.6 percent on reports Sigma was evaluating a bid for UK chemist chain Boots, a move viewed as high risk and dilutive to returns. Hyperion Asset Management confirmed Sigma engaged in preliminary discussions regarding a potential Boots acquisition on 10 June, before the board withdrew its interest and ceased discussions entirely just five days later. Ten Cap named Sigma its top buy idea, arguing the weakness around the reported Boots approach created an attractive opportunity, particularly once the company walked away, reinforcing management discipline in not chasing offshore scale at any price, with the core Sigma and Chemist Warehouse story remaining compelling. Alvia Asset Partners held a sell recommendation centred on the risk the company might still consider a large UK gamble, describing Chemist Warehouse's Bunnings-like approach to pharmacy retailing as having achieved category-killer status in Australia.

Recent share price weakness around the reported Boots acquisition created an attractive opportunity, particularly now the company has walked away from the process, reinforcing management discipline: SIG is not chasing offshore scale at any price.

— Ten Cap, Article, June 2026

A first real crack in the growth story

Pendal Group said the stock fell 7.6 percent after a small 2 percent miss on FY26 sales, with May and June coming in well below the roughly 14 percent run rate seen in prior months, a deterioration to 8 to 9 percent growth driven by a later start to the flu season and a softer consumer, highlighting that Chemist Warehouse is susceptible to a slowing consumer in categories like fragrances.

Sales for May and June came in well below the run rate of 14% seen in prior months. The deterioration to 8-9% was driven by a later start to the flu season and a softer consumer, highlighting that Chemist Warehouse is susceptible to a slowing consumer.

— Pendal Group, Newsletter, August 2026

What fund managers say they are watching next is whether sales growth reaccelerates back toward the mid-teens run rate, whether Sigma revisits UK ambitions after the Boots retreat, whether its roughly 50 times earnings multiple proves justified by continued execution, and delivery of the smaller Greenlight Healthcare UK joint venture as a lower-risk foothold than the abandoned Boots gamble.